News

The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Community update on access to Spinraza in Europe

    In response to our request, Biogen has provided us with an update on access to SPINRAZA™ (nusinersen). There are now 29 European countries that have access to nusinersen via regular reimbursement. Since the last report, an updated situation can be found for Switzerland. As you can see from the table, there is a range of […]

    READ MORE

  2. AveXis’ name is changed to Novartis Gene Therapies EU Ltd

    AveXis, which has been part of Novartis since 2018, is becoming Novartis Gene Therapies, EU Ltd. (Novartis Gene Therapies) a new unit dedicated to developing innovative AAV-based gene therapies. While the name of the organisation changes, the commitment to patients and their families remains steadfast. Novartis Gene Therapies will continue to focus on the research, […]

    READ MORE

  3. EMA validates the Marketing Authorisation Application (MAA) for risdiplam for the proposed use in people living with SMA

    The European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for risdiplam for the proposed use in people living with SMA. Validation of the MAA confirms that the submission is accepted and begins the formal scientific evaluation process by EMA’s Committee for Medicinal Products for Human Use (CHMP). Following our request, Roche provided […]

    READ MORE